Dynamic Technology Lab Private Ltd purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 13,360 shares of the company’s stock, valued at approximately $432,000.
A number of other large investors have also added to or reduced their stakes in the stock. Raymond James & Associates acquired a new stake in shares of Harmony Biosciences during the 3rd quarter worth $216,000. Bank of New York Mellon Corp raised its position in shares of Harmony Biosciences by 4.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 264,395 shares of the company’s stock valued at $8,664,000 after buying an additional 10,538 shares in the last quarter. Yousif Capital Management LLC raised its position in shares of Harmony Biosciences by 4.5% in the 3rd quarter. Yousif Capital Management LLC now owns 16,683 shares of the company’s stock valued at $547,000 after buying an additional 721 shares in the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Harmony Biosciences by 14.2% during the 3rd quarter. Teacher Retirement System of Texas now owns 10,216 shares of the company’s stock worth $335,000 after acquiring an additional 1,273 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Harmony Biosciences by 8.9% during the 3rd quarter. Principal Financial Group Inc. now owns 199,750 shares of the company’s stock worth $6,546,000 after acquiring an additional 16,260 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.
Harmony Biosciences Price Performance
Shares of HRMY opened at $29.95 on Friday. The company has a quick ratio of 3.07, a current ratio of 3.11 and a debt-to-equity ratio of 0.34. The stock has a market cap of $1.70 billion, a PE ratio of 12.97, a PEG ratio of 0.52 and a beta of 0.75. Harmony Biosciences Holdings, Inc. has a 12-month low of $18.61 and a 12-month high of $39.26. The business has a 50-day simple moving average of $30.77 and a two-hundred day simple moving average of $30.99.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.07. The business had revenue of $154.62 million during the quarter, compared to the consensus estimate of $154.10 million. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. Harmony Biosciences’s quarterly revenue was up 29.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.48 earnings per share. Analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.53 earnings per share for the current fiscal year.
Insider Transactions at Harmony Biosciences
In other Harmony Biosciences news, insider Jeffrey Dierks sold 11,979 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $32.00, for a total transaction of $383,328.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 30.80% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several equities research analysts have weighed in on HRMY shares. Needham & Company LLC restated a “buy” rating and set a $50.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 30th. Cantor Fitzgerald restated an “overweight” rating and set a $49.00 price objective on shares of Harmony Biosciences in a research report on Friday, April 12th. Finally, Mizuho reduced their price objective on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. Two investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, Harmony Biosciences presently has an average rating of “Moderate Buy” and an average price target of $40.63.
Check Out Our Latest Report on Harmony Biosciences
Harmony Biosciences Profile
(Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Read More
Receive News & Ratings for Harmony Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Harmony Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.